Global TQB2450 Market Strategic Research Report

Scope of the Report

The global TQB2450 market size is predicted to grow from US$ 81.19 million in 2025 to US$ 320 million in 2032; it is expected to grow at a CAGR of 13.5% from 2026 to 2032.

TQB2450 (Bemotuzumab Injection) Is A Independently Developed Programmed Death-Ligand 1 (PD-L1) Monoclonal Antibody By Chia Tai Tianqing Pharmaceutical Group, Belonging To A Novel Immune Checkpoint Inhibitor. It Specifically Blocks The PD-1/PD-L1 Signaling Pathway, Relieves The Immune Suppression Of Tumor Cells, Activates The Body’s Anti-Tumor Immune Response, And Inhibits Tumor Proliferation And Metastasis. At Present, It Has Been Developed For Multiple Solid Tumor Indications Such As Non-Small Cell Lung Cancer, Small Cell Lung Cancer And Liver Cancer, Providing A New Immunotherapy Option For Patients With Advanced Malignant Tumors.In 2025, global TQB2450 production reached approximately 45,000–50,000 vials.

TQB2450 (Bemotuzumab), a Self-Developed PD-L1 Inhibitor By Chia Tai Tianqing, Has Established Unique Competitive Advantages In The Domestic PD-(L)1 Market Through The Differentiated Combination Strategy Of "Immunotherapy Plus Anti-Angiogenesis". With A Comprehensive Layout Of Solid Tumor Indications, The Product Covers Multiple Common And Rare Tumor Types Such As Lung Cancer, Endometrial Cancer And Sarcoma. It Delivers Significant Clinical Benefits And Controllable Safety Profile Via Highly Synergistic Combination Regimens. With The Continuous Release Of Clinical Demand And Expanding Indications, Its Market Penetration Capacity Is Growing Steadily. Supported By Localized Production, Stable Supply Chain And Convenient Medication Administration, It Further Consolidates Its Core Position In The Domestic Market. Amid The Intense Global Competition Of Immunotherapy, TQB2450 Features Innovative Combination Regimens And Continuous Clinical Breakthroughs, Making It A Benchmark Product With Strong Growth Potential In The Domestic PD-L1 Sector. It Provides Diversified Treatment Options For Patients And Promotes The Development Of Domestic Tumor Immunotherapy.

Key Questions Addressed in this Report

What is the 10-year outlook for the global TQB2450 market?

What factors are driving TQB2450 market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do TQB2450 market opportunities vary by end market size?

How does TQB2450 break out by Type, by Application?

This report presents a comprehensive overview of the global TQB2450 market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• 100 mg (10 mL)/vial
• 600 mg (20 mL)/vial

Segment by Combination Therapy

• Bemotuzumab + Anlotinib
• Bemotuzumab + Paclitaxel

Segment by Sales Channel

• Hospital
• Retail
• Online

Segment by Application

• Non-Small Cell Lung Cancer
• Small Cell Lung Cancer
• Advanced Solid Tumors
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global TQB2450 market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Advanced Solid Tumors evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact